Company
Allergan
NYSE:AGN
Allergan is a global specialty pharmaceutical company, which develops and commercialises products for eye care, neuromodulator, skin care and other specialty markets. Its products are sold in over 100 countries worldwide and include the successful and popular Botox and Botox cosmetics treatments.
91 stories
Firms fined £260mln over 10,000% rise in price of NHS drugs
"These are without doubt some of the most serious abuses we have uncovered in recent years"
LATE MOVERS: Costco climbs after bulk retailer’s Q2 earnings blow past Wall Street estimates
Also making moves were H&R Block, Burlington and GM
Genprex adds pharma veteran John Bonfiglio to board
Most recently, Bonfiglio served as CEO of Oragenics and then played a key role in TapImmune’s merger with Marker Therapeutics
Aptinyx stock falls after NYX-2925 trial for treating painful diabetic nerve damage fails to meet endpoint
However, the biotech said it will still conduct an exploratory Phase 2 study of NYX-2925 for treating patients with fibromyalgia or muscle pain
Allergan shrinks net loss in 3Q thanks to Botox sales and lifts earnings forecast
Botox was a big seller in the quarter, as its sales rose 13.6% to $879.7 million
IPO Roundup: Biotechs dominate this week's slate of 12 IPOs
A property management company and a fintech round out a heavy slate of new issues this week
Investors like the idea of Allergan selling two small units, having a laser focus on core areas
CEO Brent Saunders said the drug giant will use proceeds to buy back shares, cautioning ‘there is no fire sale’
Axovant shares jump after welcoming former Allergan and Teva execs to its management team
The biotech's CEO, COO and three board members departed the company in February
Allergan 1Q tops analyst estimates as pharma giant raises full-year guidance
Sales of Botox and Juvederm Collection rise by double-digit percentages though Restasis sales slide
Shire: Takeda deadline looms, but will other bidders emerge for in-play £43bn drugs group?
Next week we'll see the colour of Takeda's money. Will rival bidders emerge from the woodwork?
Archive
Lloyds, Barclays, RBS, GSK and Shire kick off earnings season for banks and pharmas
The week ahead in includes updates from Lloyds, Barclays, RBS, Shire, GSK, Whitbread, Persimmon and Shell
FTSE 100 puts in late spurt to close comfortably higher
Shire shares propped up the rest of the Footsie leader-board despite Takeda unveiling an improved offer for the drugs maker
ReNeuron appoints new chief medical officer based in recently established US office
The AIM-listed firm said Dr Richard Beckham will replace Dr Julian Howell, who has left the company to pursue another opportunity
Apricus goes flat as FDA refuses to approve erectile dysfunction treatment
It’s the second time regulators have given the thumbs-down to Vitaros, with the FDA flagging concerns over one of the ingredients in the cream as well as with the manufacturing process
Allergan Q4 earnings top Wall Street forecasts; migraine drug succeeds in late-stage trial
It was a double dose of good news for Allergan investors: Q4 results came in better than expected, while ubrogepant succeeded in a key trial
Allergan, Seagate Technology, Urban Outfitters - AFTER HOURS
Proactive stayed up to have a look at what was piquing interest after the bell in New York
Conagra Brands, Allergan, Accenture, Nike and more - PRE-MARKET
Proactive takes a look at the stocks piquing interest before the bell in New York
Allergan lands FDA approval for schizophrenia drug
"We are pleased that the FDA has recognized the benefits of VRAYLAR for maintenance treatment of adults with schizophrenia."
Teva Pharmaceutical tanks in Tel Aviv after third quarter earnings
Yesterday, Allergan said it would start to sell off its nearly 10% stake in Teva
Botox maker Allergan pumps up despite third quarter loss
The firm unveiled a net loss of US$4.03bn compared with a profit of US$15.15bn a year earlier
Allergan plc, Moleculin Biotech Inc, Estee Lauder Companies Inc, Abercrombie & Fitch Co - PRE-MARKET
Biotech stocks were in play before the bell in New York ..
Allergan to appeal against RESTASIS patents verdict
Allergan enlisted the aid of the Mohawk tribe in an effort to protect its patents
Allergan’s Botox gets US FDA green light to treat forehead lines
The latest approval makes the brand the first and only neurotoxin to be indicated for three facial treatment areas
Allergan shares puff up in pre-market as it announces latest share buy-back and reaffirms dividend commitment
It also reassured investors by saying it will pay down its US$3.75bn (£2.78bn) debt pile next year
Allergan accused of taking advantage of tribal sovereignty in patent dispute with Mylan
Allergan has transferred several patents relating to Restasis to the Native American St. Regis Mohawk Tribe
American Airlines Group Inc, Allergen plc, Centene Corp and Walt Disney Co - PRE-MARKET
We take a look at what's moving the dial in pre-market deals in New York
Allergan shares move lower as second quarter losses almost double year-on-year
For the three months ended June 30, the pharma group reported a second quarter loss of US$2.35, an 88% increase compared to the same period last year
Allergan edges higher on first quarter beat and full-year guidance upgrade
Excluding items, earnings per share came in at US$3.35, 5 cents ahead of the Wall Street consensus
Small Pharma raises £830,000 from angel investors to develop ketamine-based drug as severe depression treatment
The firm, a London-based start-up, said the funds raised will be supplemented by a £140,000 grant from Innovate UK to support the development of a rapid-acting drug
Allergan to push on with final trial for Botox for depression
Results were were close to those achieved from antidepressants on the market
Allergan to put forward new acne drug after good trials
Allergan intends to submit an application to the US Food & Drug Administration (FDA) in the second half of 2017.
Gene editing pioneer Editas agrees US$90m collaboration with Allergan
Editas is one of three companies currently locked in a courtroom battle over the ownership of the gene-editing technique CRISPR
Allergan to buy body contouring company Zeltiq Aesthetics
Pharmaceutical group Allergan has announced the acquisition of Zeltiq Aesthetics for $2.475bn to gain access to its body contouring technology.
US stocks close higher but off record peaks as oil prices fall
US stocks closed higher on Monday but off their intraday highs, as falling oil prices took the shine off a rally
Allergan smiling again after Botox boost
After a disappointing previous three months, the Dublin-based pharma beat expectations this time.
US stocks recover from losses as analysts focus on surprise gasoline supply drop
US stocks recovered from intraday losses to end higher on Wednesday after analysts focused on a fall in gasoline inventories rather than a spike in oil supplies
Allergan to buy LifeCell for $2.9bn cash
Allergan, the maker of wrinkle-filler Botox, said on Tuesday that it has agreed to buy regenerative medicine company LifeCell for $2.9bn in cash
Teva to defend its Actavis UK division amid claims of “unfair” price hike
The UK’s competition watchdog said the business may have broken competition laws after it hiked the price of a drug
Trending: Valeant tries to be valiant
It may seem the phrase manufactured misfortune was invented for Valeant Pharmaceuticals Intl
US stocks end mixed as winners and losers assess Trump
US stocks seesawed through Thursday, with the Dow hitting a record high intraday and close, as banks and pharma stocks lapped up the perceived benefits of President-elect Donald Trump’s victory, while tech stocks sank on worries about his f
Allergan's results miss on two fronts
Revenues of US$3.32bn, up 4.4%, came in some US$400mln shy of forecasts
Investments and investor services
FTSE 100 nears May 2015 highs after data and sterling fall
FTSE 100 shares had a good start to the fourth quarter, helped by good manufacturing data and hopes that the pound's sharp fall on Monday will help exporters
Allergan to buy Tobira for US$1.7bn
Allergan wants to gain access to Tobira’s potentially lucrative experimental NASH treatments
Archive
Vitae Pharma downgraded after Allergan takeover offer
Vitae Pharmaceuticals shares may have rocketed by 160% after Allergan said it would buy the company on Wednesday, but brokers at Wedbush downgraded the small stock to neutral and trimmed the share price target to $21
Wall St shares edge lower after oil supply data setback
US stocks edged lower on Wednesday after oil prices sagged on supply data
Tepper tips Allergan, Quorum Health
Hedge fund manager David Tepper increased his stake in the drugmaker Allergan and orchestrated a new bet on Quorum Health
Allergan earnings healthy, but revenues slightly anaemic
Company releases numbers soon after major divestitures
Teva corporate bond deal could become year’s 3rd biggest
Teva Pharmaceutical Industries Ltd. is heading towards one of the year’s largest US corporate bond deals as foreign investors stampeded for a piece of the high-quality paper
Trending: Brexit seen as a lever to more transatlantic M&A
When Brexit was first mooted by the Leave camp over a year ago, the slogan was all about taking back control of sovereignty and executive powers from the European Union. No one ever saw it as a conduit for taking control of US companies, di
US shares close higher as energy stocks perk up on pared oil price losses
US energy shares helped solidify Wall Street gains by the close on Tuesday – after earlier strife over the uncertainty contained in Fed chair Janet Yellen’s testimony on Capitol Hill - leaving the S&P 500 to notch its second straight day of
US stocks cling onto gains but unimpressed by Yellen’s outlook
Wall Street shares were clinging onto gains at midsession on Tuesday, underwhelmed by the lack of certainty in the Federal Reserve’s economic and monetary outlook after the central bank’s chair Janet Yellen read testimony before the US Sena
Impax splashes out $586mln on Allergan and Teva's generics cast-offs
Teva, which is taking over Allergan, has been ordered to sell some of Allergan's US generic drugs assets
US stocks shift higher ahead of Yellen speech
Stocks are adding to yesterday's gains, though not as briskly as had been expected before the market opened
US stocks shift higher ahead of Yellen speech
Stocks are adding to yesterday's gains, though the indices have not risen as high as had been expected ahead of the open
Pharma Pfizer unfazed after Jefferies trims price target
Pharmaceuticals behemoth Pfizer Inc shares remained resilient after broker Jefferies trimmed its price target on the pharmaceutical giant's stock to $42 from $40, as Pfizer leadership prepares to decide whether to separate its global establ
Not tonight; he's got a headache
"It's important to encourage everyone – men and women – who is experiencing symptoms to seek an accurate diagnosis."
Trending: Macys, Staples and the worst Wall Street M&A year on record
If the oil and commodities sectors have had a rough ride this year, traders' shun words on Wednesday on Wall Street were Macys, Staples, and retail as US faces up to worst M&A deal failures on record
Hardware & electrical equipment
Trending: Banking on Apple in Canada
While Facebook applied two years ago for a banking licence in the United States and has since begun developing initiatives to offer methods for its users to store cash and pay for services via the social network, Apple is formalising relati
Allergan shares rise after $10bn buyback plan
Allergan shares rise after the company says it will buy back up to $10bn in stock following a swing to a first-quarter profit on a surge in sales of key drugs, including the wrinkle and muscle spasm treatment Botox
US investors sit on their hands ahead of Fed minutes
Neither Pfizer or Allergan showed any ill effects from the collapse of the proposed merger
Wall Street shares push higher after shock US oil inventories drop, Fed sidelined
US small-cap stocks swing higher after a surprise drop in US weekly oil inventories boosts energy futures and calm jitters over minutes of the Federal Reserve's recent rate-setting meeting
US investors sit on their hands ahead of Fed minutes
Neither Pfizer or Allergan showed any ill effects from the collapse of the proposed merger
Stocks tread water ahead of Fed minutes
Neither Pfizer or Allergan showed any ill effects from the collapse of the proposed merger
Trending: Pfizer tie up with Allergan catches a cold
Not for the first time has the ambitious and acquisitive pharmaceutical behemoth Pfizer has been upset at the merger altar, but with its Allergan deal under threat, the company may well step back and assess shareholder value
Pfizer agrees US$150bn Allergan merger
The combined group will become the world’s largest drug company.
Pfizer's Allergan bid in spotlight, Wall Street trades lower
All of the three benchmark indexes are in negative territory.
U.S. Risers/Fallers: Wendy's, Sodastream, Michael Kors, Tesla, Groupon, 21st Century, Chesapeake
Below are the main news driven share price changes at 11:02 a.m. in New York on Wednesday:
Wall Street shares set for higher open; car industry in focus
Wall Street shares are set to rise again in a busy day ahead for earnings and as the global car market is once again under scrutiny.
M&A activity pushes back towards pre-crash highs
Deals on Monday took this year's M&A total above 2014
Potential merger of Allergan and Pfizer sparks tax debate
Irish based botox maker Allergan and US drugs giant Pfizer confirmed they are in merger talks.
Archive
Wall Street drops amid downbeat GDP data
The preliminary gross domestic product (GDP) number came in a bit weaker than expected.
Stocks trim losses after soft GDP data
A half-hearted rally was under way in the lunchtime trading session,
U.S. Risers/Fallers: Allergan, Pfizer, Time Warner Cable, PayPal, GoPro, Yelp, MasterCard, Aetna
Below are the main news driven share price changes at 12:04 p.m. in New York on Thursday:
Allergan, Pfizer confirm preliminary merger talks
A potential merger would create the world’s largest drug maker.
US stocks slide as GDP numbers muddy the Fed's waters
There is much to think about this morning with the prospect of a 2015 rate hike back on the table and GDP a bit weaker than expected
US stocks to step back after Fed hints of December rate rise
The Fed went off-piste as far as the market was concerned with its comments yesterday following the interest rate decision
Wall Street sinks as China selloff raises concerns on global growth
U.S. stocks slumped today, with equities headed for their longest losing streak since January, following the sharpest drop in Chinese stocks in eight years, on worries cooling growth in the world's second-largest economy would hurt it
Wall Street set to open lower on sharp China sell-off
U.S. stock-index futures fell today after a steep drop in Chinese stocks weighed on markets around the world and as investors wait for the outcome of this week's meeting of the U.S. Federal Reserve. S&P 500 futures were last down 0.5 pe
Teva to buy Allergan for $40.5 bln, drops Mylan bid
Teva Pharmaceutical Industries (NYSE:TEVA), an Israeli drugmaker, agreed to buy Dublin-based Allergan PLC's (NYSE:AGN) generic pharmaceuticals business for $40.5 billion in cash and stock, and dropped its hostile offer for Mylan (NASDAQ:MYL
Wall Street to open higher ahead of euro zone summit on Greece
U.S. stock-index futures advanced today ahead of a euro zone leaders summit at which Greece will bring a proposal in a last-ditch attempt to secure an aid package to keep the country in the currency club. Futures for the Dow Jones Industria
Wall Street drifts lower on Greece worries; BofA, Citigroup, JPMorgan decline
Wall Street retreated as Greece scrambled to avoid a cash crunch and energy shares tumbled with the price of oil. The S&P 500 (INDEXSP:.INX) slid 0.5 percent to 2,065.59 at 3:45 p.m. in New York. The 30-company Dow Jones Industrial Aver
U.S. stock-index futures drop after Greece votes ‘no’; BofA, Citi, JPMorgan slide
U.S. stock-index futures slipped after Greece rejected debt bailout terms, throwing the future of the country's euro zone membership into further doubt. Futures for the Dow Jones Industrial Average lost 0.8 percent to 17,508, while those fo
Wall Street trades higher after Fed statement; Synergy Pharma surges
Wall Street were trading higher before the close today as the Federal Reserve signaled that interest rates would increase more slowly than many investors had been expecting. The S&P 500 (INDEXSP:.INX) rose 0.3 percent to 2,102.11 at 3:4
U.S. stock-index futures inch higher ahead of Fed statement, amid Greece stalemate
U.S. stock index-futures edged higher today but investors remained cautious ahead of a Federal Reserve statement that could provide hints on the timing of a rate hike, and amid signs the impasse in Greek aid talks was deepening. Futures for